Bitcoin price today: hits record high over $124k on rate cut bets, corporate cheer
Benjamin Halladay, the Chief Financial Officer of Esperion Therapeutics, Inc. (NASDAQ:ESPR), a $367 million market cap biopharmaceutical company that has shown impressive revenue growth of 187% over the last twelve months, recently sold a small number of company shares. According to a Form 4 filing with the Securities and Exchange Commission, Halladay sold 11 shares of common stock on February 19, 2025, at a price of $1.86 per share. This transaction was valued at $20 in total.
The filing notes that the shares were sold to satisfy tax obligations on vested shares of restricted stock units. Following this transaction, Halladay holds 240,671 shares of Esperion Therapeutics directly.
In other recent news, Esperion Therapeutics has reported several significant developments that investors should note. The company has issued $100 million in 5.75% Convertible Senior Subordinated Notes due 2030, as part of a private exchange and subscription transaction, strengthening its financial position. Additionally, Esperion provided updated financial guidance for the fiscal year ending December 31, 2025, projecting operating expenses between $215 million and $235 million, which marks a substantial increase in spending. This announcement has raised concerns about the company’s cost management and its potential impact on profitability.
Esperion’s drug bempedoic acid has shown promising results in a subset analysis from the CLEAR Outcomes Trial, published in the Journal of the American Heart Association. This has led H.C. Wainwright to maintain a Buy rating on Esperion shares, with a price target of $16.00, reflecting confidence in the drug’s potential. Conversely, JMP Securities has adjusted its price target for Esperion to $4.00, down from $7.00, while maintaining a Market Outperform rating, citing a consistent increase in prescriptions for NEXLETOL and NEXLIZET. The firm anticipates continued demand growth due to expanded product labels and broader reimbursement coverage.
Moreover, JMP Securities reiterated its $7.00 price target following a key opinion leader event, emphasizing the efficacy and safety of Esperion’s NEXLETOL/NEXLIZET. The analyst highlighted the growing real-world clinical validation of bempedoic acid’s use, supporting a positive outlook for the company. These recent developments underscore Esperion’s ongoing efforts in drug development and financial strategy, as it navigates the complexities of the pharmaceutical industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.